

Daniel Hochhauser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/250072/publications.pdf>

Version: 2024-02-01

94
papers

7,027
citations

81900

39
h-index

60623

81
g-index

129
all docs

129
docs citations

129
times ranked

10925
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of PARP inhibitors in gastrointestinal cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103621.	4.4	7
2	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3929-3939.	1.6	66
3	POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 412-412.	1.6	1
4	Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 378-378.	1.6	59
5	Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥ 10 . <i>Clinical Cancer Research</i> , 2021, 27, 1923-1931.	7.0	53
6	Effects of N-terminus modified Hx-amides on DNA binding affinity, sequence specificity, cellular uptake, and gene expression. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 47, 128158.	2.2	1
7	Multimodal Treatment in Metastatic Colorectal Cancer (mCRC) Improves Outcomes—The University College London Hospital (UCLH) Experience. <i>Cancers</i> , 2020, 12, 3545.	3.7	9
8	Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095680.	3.2	29
9	Geographic and Ethnic Heterogeneity of Germline <i>BRCA1</i> or <i>BRCA2</i> Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1442-1454.	1.6	52
10	Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation. <i>Scientific Reports</i> , 2020, 10, 663.	3.3	23
11	Liver resection surgery compared with thermal ablation in high surgical risk patients with colorectal liver metastases: the LAVA international RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-38.	2.8	17
12	261—Association of T-cell—“inflamed gene expression profile and PD-L1 status with efficacy of pembrolizumab in patients with esophageal cancer from KEYNOTE-180. , 2020, , .		1
13	Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 317-327.	27.0	1,521
14	Communication with children and adolescents about the diagnosis of their own life-threatening condition. <i>Lancet, The</i> , 2019, 393, 1150-1163.	13.7	100
15	Communication with children and adolescents about the diagnosis of a life-threatening condition in their parent. <i>Lancet, The</i> , 2019, 393, 1164-1176.	13.7	99
16	Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus. <i>JAMA Oncology</i> , 2019, 5, 546.	7.1	366
17	Measurement of Tumor Antioxidant Capacity and Prediction of Chemotherapy Resistance in Preclinical Models of Ovarian Cancer by Positron Emission Tomography. <i>Clinical Cancer Research</i> , 2019, 25, 2471-2482.	7.0	32
18	Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4032-4032.	1.6	4

#	ARTICLE	IF	CITATIONS
19	Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.. Journal of Clinical Oncology, 2019, 37, LBA4-LBA4.	1.6	11
20	Health-related quality of life (HRQoL) of pembrolizumab (pembro) versus physician choice single-agent paclitaxel, docetaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma (ACC) or squamous cell carcinoma (SCC) of the esophagus that has progressed after first-line standard therapy (KEYNOTE-181).. Journal of Clinical Oncology, 2019, 37, 4048-4048.	1.6	0
21	Liver resection surgery versus thermal ablation for colorectal LiVer MetAstases (LAVA): study protocol for a randomised controlled trial. Trials, 2018, 19, 105.	1.6	45
22	Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut, 2018, 67, 179-193.	12.1	73
23	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2018, 392, 123-133.	13.7	984
24	Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase 2 KEYNOTE-180 study.. Journal of Clinical Oncology, 2018, 36, 4049-4049.	1.6	9
25	Geographic and ethnic heterogeneity in the <i>BRCA1/2</i> pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology, 2018, 36, 4115-4115.	1.6	15
26	MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models. Oncotarget, 2018, 9, 11592-11603.	1.8	27
27	mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism. Cell Death and Differentiation, 2017, 24, 1045-1062.	11.2	55
28	Autophagy and receptor tyrosine kinase signalling: A mTORC2 matter. Cell Cycle, 2017, 16, 1855-1856.	2.6	7
29	Stress-specific p38 MAP kinase activation is sufficient to drive EGF receptor endocytosis but not nuclear translocation. Journal of Cell Science, 2017, 130, 2481-2490.	2.0	11
30	Modulation of topoisomerase III α expression and chemosensitivity through targeted inhibition of NF-Y:DNA binding by a diamino p-anisyl-benzimidazole (Hx) polyamide. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2017, 1860, 617-629.	1.9	8
31	Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. BMC Medical Informatics and Decision Making, 2017, 17, 149.	3.0	23
32	Biological and Prognostic Significance of the Morphological Types and Vascular Patterns in Colorectal Liver Metastases (CRLM). Medicine (United States), 2016, 95, e2924.	1.0	24
33	The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacyâ€”Response. Clinical Cancer Research, 2016, 22, 2595-2595.	7.0	4
34	Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERICâ€”A Singleâ€”Center, Blinded, Randomized Controlled Trial. Clinical Cardiology, 2016, 39, 72-82.	1.8	29
35	POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline <i>BRCA1/2</i> mutation (g<i>BRCA</i>m).. Journal of Clinical Oncology, 2016, 34, TPS4152-TPS4152.	1.6	15
36	NF-Y activates genes of metabolic pathways altered in cancer cells. Oncotarget, 2016, 7, 1633-1650.	1.8	50

#	ARTICLE	IF	CITATIONS
37	The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1). <i>Clinical Cancer Research</i> , 2015, 21, 5563-5577.	7.0	51
38	Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv394.	6.3	50
39	Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy. <i>Cancer Discovery</i> , 2015, 5, 821-831.	9.4	227
40	Significant Therapeutic Efficacy with Combined Radioimmunotherapy and Cetuximab in Preclinical Models of Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1239-1245.	5.0	14
41	Nuclear Localization and Gene Expression Modulation by a Fluorescent Sequence-Selective p-Anisyl-benzimidazolecarboxamido Imidazole-Pyrrole Polyamide. <i>Chemistry and Biology</i> , 2015, 22, 862-875.	6.0	15
42	WASH and Tsg101/ALIX-dependent diversion of stress-internalized EGFR from the canonical endocytic pathway. <i>Nature Communications</i> , 2015, 6, 7324.	12.8	63
43	Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer. <i>Cancer Research</i> , 2015, 75, 1255-1264.	0.9	39
44	Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma. <i>British Journal of Cancer</i> , 2015, 113, 1305-1312.	6.4	23
45	GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 669-669.	1.6	11
46	Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment. <i>Oncotarget</i> , 2015, 6, 10548-10562.	1.8	26
47	Abstract 3596: A biomarker study of lapatinib in the neoadjuvant treatment of HER2 over expressing esophago-gastric adenocarcinoma (EGA)., 2015, , .		0
48	Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage. <i>Clinical Cancer Research</i> , 2014, 20, 3496-3506.	7.0	28
49	An Extended Pyrrolobenzodiazepineâ€“Polyamide Conjugate with Selectivity for a DNA Sequence Containing the ICB2 Transcription Factor Binding Site. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6339-6351.	6.4	30
50	Î³-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000). <i>Clinical Cancer Research</i> , 2013, 19, 721-730.	7.0	52
51	A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2013, 108, 1252-1259.	6.4	121
52	The diagnosis and management of gastric cancer. <i>BMJ</i> , The, 2013, 347, f6367-f6367.	6.0	122
53	Treatment with Gefitinib or Lapatinib Induces Drug Resistance through Downregulation of Topoisomerase III± Expression. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2897-2908.	4.1	12
54	A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the<i>O</i></i>6-Methylguanine-DNA Methyltransferase Promoter. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 809-818.	4.1	48

#	ARTICLE	IF	CITATIONS
55	Abstract 5468: Interaction between cetuximab and chemotherapy in colon cancer.. , 2013, , .		0
56	Evidence for different mechanisms of "unhooking"™ for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. BMC Cancer, 2012, 12, 436.	2.6	20
57	Small molecule drugs " optimizing DNA damaging agent-based therapeutics. Current Opinion in Pharmacology, 2012, 12, 398-402.	3.5	29
58	The interaction of EGFR and repair of DNA damage following chemotherapy and radiation. Drug Discovery Today: Disease Models, 2012, 9, e69-e73.	1.2	1
59	Abstract 1766: Persistence of drug-induced DNA interstrand cross-links distinguishes bendamustine from conventional DNA cross-linking agents. , 2012, , .		3
60	EGFR Nuclear Translocation Modulates DNA Repair following Cisplatin and Ionizing Radiation Treatment. Cancer Research, 2011, 71, 1103-1114.	0.9	249
61	Abstract 665: Targeting the Mlul cell cycle box (MCB) sequence 5"™-ACGCGT-3"™ in the human Dbf4 promoter using the rationally designed polyamide formamido-imidazole-pyrrole-imidazole (f-PI). , 2011, , .		0
62	Targeting the ICB2 site of the topoisomerase III± promoter with a formamido-pyrrole"imidazole"pyrrole H-pin polyamide. Bioorganic and Medicinal Chemistry, 2010, 18, 5553-5561.	3.0	23
63	Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. British Journal of Cancer, 2010, 102, 1106-1112.	6.4	173
64	Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2009, 15, 2140-2147.	7.0	68
65	Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. Molecular Cancer Therapeutics, 2009, 8, 3015-3023.	4.1	55
66	Targeting the inverted CCAAT Box-2 of the topoisomerase III± gene: DNA sequence selective recognition by a polyamide"intercalator as a staggered dimer. Bioorganic and Medicinal Chemistry, 2008, 16, 2093-2102.	3.0	18
67	Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolbenzodiazepine-polyamide conjugate CWL-78. Molecular Cancer Therapeutics, 2008, 7, 1319-1328.	4.1	52
68	The role of 99mTc-depreotide in the management of neuroendocrine tumours. Nuclear Medicine Communications, 2008, 29, 436-440.	1.1	16
69	Modulation of topoisomerase III± expression by a DNA sequence-specific polyamide. Molecular Cancer Therapeutics, 2007, 6, 346-354.	4.1	27
70	Binding of f-PIP, a pyrrole- and imidazole-containing triamide, to the inverted CCAAT box-2 of the topoisomerase III± promoter and modulation of gene expression in cells. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 6161-6164.	2.2	21
71	Synthesis and Evaluation of an Intercalator-Polyamide Hairpin Designed to Target the Inverted CCAAT Box 2 in the Topoisomerase III± Promoter. ChemBioChem, 2006, 7, 1722-1729.	2.6	10
72	Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Molecular Cancer Therapeutics, 2006, 5, 209-218.	4.1	96

#	ARTICLE	IF	CITATIONS
73	Design of a Hairpin Polyamide, ZT65B, for Targeting the Inverted CCAAT Box (ICB) Site in the Multidrug Resistant (MDR1) Gene. <i>ChemBioChem</i> , 2005, 6, 2305-2311.	2.6	11
74	Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agents. <i>International Journal of Oncology</i> , 2005, 27, 337.	3.3	2
75	Modulation of DNA Repair In vitro after Treatment with Chemotherapeutic Agents by the Epidermal Growth Factor Receptor Inhibitor Gefitinib (ZD1839). <i>Clinical Cancer Research</i> , 2004, 10, 6476-6486.	7.0	79
76	SJG-136 (NSC 694501), a Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity. <i>Cancer Research</i> , 2004, 64, 6693-6699.	0.9	123
77	Targeting the Inverted CCAAT Box 2 in the Topoisomerase II β Promoter by JH-37, an Imidazole α -Pyrrole Polyamide Hairpin: Design, Synthesis, Molecular Biology, and Biophysical Studies. <i>Biochemistry</i> , 2004, 43, 12249-12257.	2.5	30
78	Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. <i>Lancet Oncology</i> , The, 2004, 5, 409-418.	10.7	143
79	A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. <i>British Journal of Cancer</i> , 2002, 87, 600-607.	6.4	151
80	Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. <i>Blood</i> , 2002, 100, 224-229.	1.4	120
81	Transcriptional Regulation of Topoisomerase II β at Confluence and Pharmacological Modulation of Expression by bis-Benzimidazole Drugs. <i>Molecular Pharmacology</i> , 2001, 59, 699-706.	2.3	51
82	Relevance of mitochondrial DNA in cancer. <i>Lancet</i> , The, 2000, 356, 181-182.	13.7	40
83	Effects of wild-type p53 expression on the quantity and activity of topoisomerase II α and β in various human cancer cell lines. <i>Journal of Cellular Biochemistry</i> , 1999, 75, 245-257.	2.6	16
84	Effects of wild-type p53 expression on the quantity and activity of topoisomerase II α and β in various human cancer cell lines. <i>Journal of Cellular Biochemistry</i> , 1999, 75, 245-257.	2.6	4
85	Arsenic compound effective in leukaemia. <i>Lancet</i> , The, 1998, 351, 1037.	13.7	0
86	Molecular biologists map pathways to gastrointestinal cancer. <i>Lancet</i> , The, 1998, 351, 1109.	13.7	1
87	Modulation of chemosensitivity through altered expression of cell cycle regulatory genes in cancer. <i>Anti-Cancer Drugs</i> , 1997, 8, 903-910.	1.4	25
88	Colon cancer genotypes change in two ways. <i>Lancet</i> , The, 1997, 349, 1151.	13.7	0
89	Phorbol ester-induced down-regulation of topoisomerase II β mRNA in a human erythroleukemia cell line. <i>Biochemical Pharmacology</i> , 1996, 52, 1065-1072.	4.4	5
90	Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 1996, 14, 1877-1884.	1.6	138

#	ARTICLE	IF	CITATIONS
91	Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 10436-10440.	7.1	98
92	The role of topoisomerase II α and II β in drug resistance. Cancer Treatment Reviews, 1993, 19, 181-194.	7.7	42
93	Structure of the human DNA repair geneHAP1and its localisation to chromosome 14q 11.2â€“12. Nucleic Acids Research, 1992, 20, 4417-4421.	14.5	58
94	Mechanisms of Multidrug Resistance in Cancer Treatment. Acta OncolÃ³gica, 1992, 31, 205-213.	1.8	189